GlassScriptPhysician profile
Hassan Elnour
NPI 1326302894
$2,713.66
in general payments reported to CMS, 2019-2025
27 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $676 · 2021: $564 · 2022: $154 · 2023: $241 · 2024: $513 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.91 | 2021-2025 | |
| Lilly USA, LLC | $308.96 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Teva Pharmaceuticals USA, INC. | $271.91 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $209.93 | 2023-2025 | Xcopri |
| Ucb, INC. | $175.11 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Catalyst Pharmaceuticals, INC. | $164.32 | 2023-2025 | Fycompa |
| Biogen, INC. | $129.59 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $117.44 | 2020-2022 | |
| Allergan, INC. | $110.48 | 2020 | |
| Harmony Biosciences LLC | $81.42 | 2020-2021 | |
| Genzyme Corporation | $65.12 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $57.49 | 2023 | Aptiom |
| Neurelis, INC. | $53.52 | 2022-2023 | Valtoco |
| Avanir Pharmaceuticals, INC. | $51.09 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $49.57 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $47.88 | 2025 | Ultomiris |
| Lundbeck LLC | $42.83 | 2022-2024 | Vyepti |
| Ge Healthcare | $39.19 | 2021 | |
| Celgene Corporation | $34.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $34.13 | 2021 | |
| Eisai INC. | $25.87 | 2024 | |
| Emd Serono, INC. | $20.36 | 2020 | |
| Pfizer INC. | $19.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.17 | 2020 | |
| Genentech USA, INC. | $15.77 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.64 | 2020 | |
| Neurocrine Biosciences, INC. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Elnour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.